Evidence availability for 1-year obesity treatment-initiation decisions: an estimand-aligned Bayesian longitudinal network meta-analysis

Background Obesity pharmacotherapy strategies differ in maintenance dose, titration, and lifestyle support, but existing syntheses primarily compare drugs rather than treatment-initiation decisions. We assessed 1-year weight reduction, permanent discontinuation, and incremental dose-related trade-offs while mapping the availability of eligible trial evidence. Methods We searched eight databases and two trial registries through October 2026 for randomised trials (at least 12 weeks) of obesity pharmacotherapy initiation in adults with overweight or obesity. Maintenance, withdrawal, and switching trials were excluded. Two reviewers independently selected studies, extracted data, and assessed bias and certainty. Bayesian longitudinal network meta-analysis estimated treatment-policy-compatible weight change at 52 weeks. Additional analyses examined discontinuation, dose escalation, titration, lifestyle support, and diabetes-related attenuation. The study was registered with PROSPERO (CRD420261532130). Findings We included 180 reports from 178 trials (196 randomisation units; 81,014 participants). Only 78 units reached the 1-year evidence layer, 50 informed the primary longitudinal model in adults without diabetes, and 45 of 160 target strategies had non-extrapolated 52-week estimates. Placebo-adjusted weight reductions were greatest with retatrutide 12 mg (-19.80 percentage points, 95% CrI -21.81 to -17.78), tirzepatide 15 mg (-16.87, -18.07 to -15.51), and cagrilintide-semaglutide 2.4/2.4 mg (-16.37, -18.10 to -14.70). Only tirzepatide 15 mg and semaglutide 2.4 mg had high-certainty evidence. Thirteen of 32 strategies increased adverse-event-related permanent discontinuation versus placebo; none increased all-cause discontinuation. Five of 22 adjacent dose steps had at least 0.80 probability of adding more than 2 percentage points of weight reduction. Eight 1-year titration contrasts and three trials of randomised lifestyle-support increments were identified. Weight reduction in adults with type 2 diabetes was 62% of that without diabetes (ratio 0.62, 95% CI 0.58-0.66). Interpretation Evidence directly supporting 1-year obesity treatment-initiation decisions remains limited. Higher-dose and multi-receptor strategies achieve substantial weight reduction, but certainty and discontinuation trade-offs vary. Better treatment-policy reporting and randomised evidence on titration and lifestyle support are needed.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-13
DOI
https://doi.org/10.64898/2026.11.13.26367524
Primary Topic
Pharmacology and Obesity Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Evidence availability for 1-year obesity treatment-initiation decisions: an estimand-aligned Bayesian longitudinal network meta-analysis

Minhui Dai, Dongliang Liu, Zhuying Xia, Xinbo Yin et al.
3 links
medRxiv
Pharmacology and Obesity Treatment
preprint

Evidence availability for 1-year obesity treatment-initiation decisions: an estimand-aligned Bayesian longitudinal network meta-analysis

Minhui Dai, Dongliang Liu, Zhuying Xia, Xinbo Yin, Xiaokai Wang, Guoqing Huang, Xiangmin Li
preprint en

Abstract

Background Obesity pharmacotherapy strategies differ in maintenance dose, titration, and lifestyle support, but existing syntheses primarily compare drugs rather than treatment-initiation decisions. We assessed 1-year weight reduction, permanent discontinuation, and incremental dose-related trade-offs while mapping the availability of eligible trial evidence. Methods We searched eight databases and two trial registries through October 2026 for randomised trials (at least 12 weeks) of obesity pharmacotherapy initiation in adults with overweight or obesity. Maintenance, withdrawal, and switching trials were excluded. Two reviewers independently selected studies, extracted data, and assessed bias and certainty. Bayesian longitudinal network meta-analysis estimated treatment-policy-compatible weight change at 52 weeks. Additional analyses examined discontinuation, dose escalation, titration, lifestyle support, and diabetes-related attenuation. The study was registered with PROSPERO (CRD420261532130). Findings We included 180 reports from 178 trials (196 randomisation units; 81,014 participants). Only 78 units reached the 1-year evidence layer, 50 informed the primary longitudinal model in adults without diabetes, and 45 of 160 target strategies had non-extrapolated 52-week estimates. Placebo-adjusted weight reductions were greatest with retatrutide 12 mg (-19.80 percentage points, 95% CrI -21.81 to -17.78), tirzepatide 15 mg (-16.87, -18.07 to -15.51), and cagrilintide-semaglutide 2.4/2.4 mg (-16.37, -18.10 to -14.70). Only tirzepatide 15 mg and semaglutide 2.4 mg had high-certainty evidence. Thirteen of 32 strategies increased adverse-event-related permanent discontinuation versus placebo; none increased all-cause discontinuation. Five of 22 adjacent dose steps had at least 0.80 probability of adding more than 2 percentage points of weight reduction. Eight 1-year titration contrasts and three trials of randomised lifestyle-support increments were identified. Weight reduction in adults with type 2 diabetes was 62% of that without diabetes (ratio 0.62, 95% CI 0.58-0.66). Interpretation Evidence directly supporting 1-year obesity treatment-initiation decisions remains limited. Higher-dose and multi-receptor strategies achieve substantial weight reduction, but certainty and discontinuation trade-offs vary. Better treatment-policy reporting and randomised evidence on titration and lifestyle support are needed.

medRxiv
Xiangya Hospital Central South University (CN)
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon